Substantial amendments normally require a favourable
opinion from the main REC before they can be implemented.
The only exceptions to this are:
- where urgent
safety measures need to be taken;
- in the case of substantial amendments to CTIMPs
which require authorisation by the competent authority (the Medicines
and Healthcare products Regulatory Agency (MHRA)) but do not require
ethical review.
